How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.
How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.
However, sales data suggests that repeat prescriptions drastically reduce after the first 3-6 months. Although the product has a known SE profile, our client believes that this can be well managed and controlled.
How we assessed the opportunity for a rare disease product in emerging markets
Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.
How we evaluated the potential for an existing AI product to treat a rare disease
Our client had an existing product in the market for the treatment of an autoimmune condition and wished to explore the opportunities for using this drug to treat another more low-prevalence orphan disease where there is no current targeted treatment available. The client wished to determine the market potential for the existing drug and the challenges they may face.
EphMRA 2017 round up
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands. Director and EphMRA board member, Richard Head, Director, Jennifer Redfearn and Associate Director, An-hwa Lee represented us at the conference.